Using a JNK specific inhibitor, Hagiwara et al. [20] found that the xenografted CD133+ cells could be reduced in athymic mice, which identified that the therapeutic reaction of HCC patients to sorafenib was negatively correlated with CD133 expression and JNK pathway activity. Here, PROM1 is linked to hepatocellular carcinoma.